Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC (CONTACT-02)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT04446117

Recruitment Status : Recruiting

First Posted : June 24, 2020

Last Update Posted : December 2, 2021

See Contacts and Locations

Sponsor:

Collaborators:

Roche-Genentech

Takeda

Information provided by (Responsible Party):

Exelixis

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Recruiting
Estimated Primary Completion Date :	March 30, 2022
Estimated Study Completion Date :	July 30, 2023

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Agarwal N, Azad A, Carles J, Chowdhury S, McGregor B, Merseburger AS, Oudard S, Saad F, Soares A, Benzaghou F, Kerloeguen Y, Kimura A, Mohamed N, Panneerselvam A, Wang F, Pal S. A Phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer. Future Oncol. 2022 Jan 17. doi: 10.2217/fon-2021-1096. [Epub ahead of print]

To Top